GlassScriptPhysician profile
Lynne M Talley
NPI 1720419203
$2,576.58
in general payments reported to CMS, 2019-2025
30 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $652 · 2022: $548 · 2023: $347 · 2024: $720 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.54 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $403.77 | 2021-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $388.89 | 2021-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $238.02 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $215.72 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $139.47 | 2023-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.83 | 2021-2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $135.31 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $125.01 | 2021 | |
| Lilly USA, LLC | $119.22 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $98.97 | 2024 | Opsumit |
| Pfizer INC. | $87.06 | 2021-2024 | |
| Mannkind Corporation | $73.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $56.58 | 2021 | |
| Abbott Laboratories | $39.49 | 2021-2025 | Merlin@Home |
| Amgen INC. | $34.39 | 2025 | Repatha |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.32 | 2022 | |
| Kestra Medical Technology Services, INC. | $23.78 | 2024 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $21.68 | 2024 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $21.21 | 2024 | Arcalyst |
| Philips North America LLC | $20.03 | 2025 | Lm Undivided |
| Xeris Pharmaceuticals, INC. | $18.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.49 | 2024 | Camzyos |
| Tris Pharma INC | $17.38 | 2021 | |
| Evoke Pharma, INC. | $16.46 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.29 | 2024 | |
| Abbvie INC. | $15.21 | 2022 | |
| Amarin Pharma, INC. | $14.50 | 2021 | |
| Scpharmaceuticals INC. | $14.46 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynne Talley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.